Marcus Price

Marcus Price

Auto-generated profile, based on publicly available information

Marcus Price

Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
RMRobert Morgan
Robert Morgan
ACAndrew R. Clamp
Andrew R. Clamp
DWDaniel J. White
Daniel J. White
MPMarcus Price
Marcus Price
GBGeorge J. Burghel
George J. Burghel
GJGordon C. Jayson
Gordon C. Jayson
Purpose: A single maintenance course of a PARP inhibitor (PARPi) improves progression-free survival (PFS) in germline BRCA1/2-mutant high-grade serous ovarian cancer (gBRCAm-HGSOC). The feasibility of a second maintenance course of PARPi was unknown. Patients and Methods: Phase II trial with two entry points (EP1, EP2). Patients were recruited prior to rechallenge platinum. Patients with relapsed, gBRCAm-HGSOC were enrolled at EP1 if they were PARPi-naïve. Patients enrolled at EP2 had received their first course of olaparib prior to trial entry. EP1 patients were retreated with olaparib after RECIST complete/partial response (CR/PR) to platinum. EP2 patients were retreated with olaparib ± cediranib after RECIST CR/PR/stable disease to platinum and according to the platinum-free interval. Co-primary outcomes were the proportion of patients who received a second course of olaparib and the proportion who received olaparib retreatment for ≥6 months. Functional homologous recombination deficiency (HRD), somatic copy-number alteration (SCNA), and BRCAm reversions were investigated in tumor and liquid biopsies. Results: Twenty-seven patients were treated (EP1 = 17, EP2 = 10), and 19 were evaluable. Twelve patients (63%) received a second course of olaparib and 4 received olaparib retreatment for ≥6 months. Common grade ≥2 adverse events during olaparib retreatment were anemia, nausea, and fatigue. No cases of MDS/AML occurred. Mean duration of olaparib treatment and retreatment differed (12.1 months vs. 4.4 months; P < 0.001). Functional HRD and SCNA did not predict PFS. A BRCA2 reversion mutation was detected in a post-olaparib liquid biopsy. Conclusions: A second course of olaparib can be safely administered to women with gBRCAm-HGSOC but is only modestly efficacious. See related commentary by Gonzalez-Ochoa and Oza, p. 2563

25 November 2025
Verified
Other
Open access
RMRobert Morgan
Robert Morgan
ACAndrew R. Clamp
Andrew R. Clamp
DWDaniel J. White
Daniel J. White
MPMarcus Price
Marcus Price
GBGeorge J. Burghel
George J. Burghel
GJGordon C. Jayson
Gordon C. Jayson
Functional homologous recombination repair.

25 November 2025
Verified
Other
Open access
RMRobert Morgan
Robert Morgan
ACAndrew R. Clamp
Andrew R. Clamp
DWDaniel J. White
Daniel J. White
MPMarcus Price
Marcus Price
GBGeorge J. Burghel
George J. Burghel
GJGordon C. Jayson
Gordon C. Jayson
Cell-free circulating DNA yields at each time point.

25 November 2025
Verified
Other
Open access
RMRobert Morgan
Robert Morgan
ACAndrew R. Clamp
Andrew R. Clamp
DWDaniel J. White
Daniel J. White
MPMarcus Price
Marcus Price
GBGeorge J. Burghel
George J. Burghel
GJGordon C. Jayson
Gordon C. Jayson
Progression-free survival according to functional homologous recombination repair and somatic copy-number alteration status.

1 April 2023
Verified
Other
Open access
RMRobert Morgan
Robert Morgan
ACAndrew R. Clamp
Andrew R. Clamp
DWDaniel J. White
Daniel J. White
MPMarcus Price
Marcus Price
GBGeorge J. Burghel
George J. Burghel
GJGordon C. Jayson
Gordon C. Jayson
Cell-free circulating DNA copy-number profiles.